Every year in the U.S., UTIs account for more than 10 million doctor visits. In many of those cases, antibiotics are prescribed before lab results are available – and as many as 30% turn out to be the wrong choice. That not only impacts patient recovery but also fuels the broader problem of antimicrobial resistance. Streamline Scientific’s enhanced reporting service addresses this by weaving CLSI M100 guidelines directly into PCR reports, giving providers clearer, more actionable information on the pathogens detected and their resistance markers. CLSI M100 is the leading industry guidance used for microbiology culture and sensitivity of UTIs. The mission of the CLSI M100 subcommittee is to provide useful information to enable laboratories to assist the clinician in the selection of appropriate antimicrobial therapy for patient care.
The enhanced reporting provides physicians with a more intuitive format that connects lab results to clinical guidelines. Instead of leaving providers to interpret raw PCR results, the reports connect each pathogen with relevant resistance markers and CLSI-based treatment guidance. For example, when E. coli is detected with sulfonamide or trimethoprim resistance, the report flags those drug classes as ineffective and points to better-supported alternatives. The result is faster, more confident prescribing that supports both patient care and antibiotic stewardship.
